X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: US operations zoom - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 29, 2002

    Ranbaxy: US operations zoom

    Ranbaxy has reported a 24% jump in sales and 72% growth in bottomline for 1QFY03. Operating margins improved by 240 basis points. Though results on a standalone basis are below market expectations, the highlight of the performance is strong sales growth posted by its US subsidiaries.

    (Rs m) 1QFY02 1QFY03 % change
    Net Sales 4,457 5,529 24.1%
    Other Income 166 214 28.9%
    Expenditure 3,940 4,757 20.7%
    Operating Profit (EBDIT) 517 772 49.3%
    Operating Profit Margin (%) 11.6% 14.0%  
    Interest 133 131 -1.5%
    Depreciation 169 198 17.2%
    Profit before Tax 381 657 72.4%
    Extraordinary Income/Provisions 233 564  
    Provisions/Contigencies 0 0  
    Tax 57 272 377.2%
    Profit after Tax/(Loss) 557 949 70.4%
    Net profit margin (%) 12.5% 17.2%  
    No. of Shares (eoy) (m) 116 116  
    Diluted Earnings per share* 19.2 32.7  
    P/E (at current price)   25.7  
    (*- annualised)      

    On a consolidated basis, Global sales stood at US$ 159 m, recording a 25% growth. This was driven primarily by growth in sales of dosage forms, comprising 80% of global sales, which grew by 48%. International operations accounted for 68% of the global sales. The US operations achieved impressive sales of US$ 51 m during the quarter, reflecting a growth of 158%. In the process, USA became the largest market of the company for the first time, overtaking India which recorded sales of US$ 40 m.

    Ranbaxy 1QFY03- On a standalone basis
    (Rs m) 1QFY02 1QFY03 % change
    Exports 2,273 3,176 39.7%
    Domestic 2,184 2,353 7.7%
    Total 4,457 5,529 24.1%

    It may be recalled that the company recently received FDA approval for marketing Cefuroxime Axetil tablets in the US markets after a prolonged legal battle. Ceftum (generic Cefuroxime) is a molecule with a market size of US$ 400 m. Though the approval doesn’t ensure six-month marketing exclusivity for Ranbaxy, the only generic competitor (Apotex) is atleast 3-4 months away. The market for the drug is expected to be a duopoly atleast for a year.The company has already launched the drug at about 30% price discount to GSK's Ceftin and has captured more than 50% market share in the last month.

    Besides Cefuroxime, Ranbaxy received three more approvals during the quarter from the US FDA bringing the cumulative approvals to 43. There are 29 more generics awaiting approvals.

    The Company's domestic pharmaceutical business during the quarter outpaced the market, growing at 14%. The new introductions, Cifran OD, Zanocin OD (anti-bacterials) and Pioglar (anti-diabetic), which are brand leaders in their respective segments, performed well. The Company continued to strengthen its chronic therapy segment for the Indian market with the launch of new products in the anti-hypertensive, anti-diabetic and anti-asthma segments. Introduction of Romilast (Montelukast) heralded the Company's entry into the important anti-asthma segment. However, overall the domestic market sales recorded a growth of 7.7%, implying a lower sales growth in bulk segment.

    On the research front, the 500 mg Cipro-D molecule licensed to Bayer AG has completed its clinical trials and the Bayer has filed an NDA (New Drug Application). It may be noted that following approval from the authorities, it would reach the commercialisation stage. This could trigger a considerable milestone payment for Ranbaxy. Considering the time taken by regulatory authorities for approval we expect launch of Cipro-D by mid-2003, ahead of original Ciprofloxacin patent expiry in 2003 end. There is also a possibility for licensing deal of its BPH molecule, RBX-2258 (Phase II in India) in the current quarter given that the company is in advanced negotiations stage with several MNCs.

    At the current market price of Rs 840, the stock trades at 24x its consolidated expected earnings for FY03 (Dec'02).

     

     

    Equitymaster requests your view! Post a comment on "Ranbaxy: US operations zoom". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    RANBAXY LAB SHARE PRICE


    Apr 1, 2015 (Close)

    TRACK RANBAXY LAB

    • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MARKET STATS